Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 expression and FGFR-mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica - 1 Aug 2022

Grantzau Trine, Toft Birgitte Grønkaer, Melchior Linea Cecilie, Elversang Johanna, Stormoen Dag Rune, Omland Lise Høj, Pappot Helle

Abstract excerpt

Checkpoint inhibitors have changed the treatment landscape of advanced urothelial carcinoma (mUC), and recently, a fibroblast-growth-factor-receptor (FGFR) inhibitor has been introduced. This study aimed at estimating programmed death-ligand 1 (PD-L1) expression in primary tumors (PTs) and the PD-L1 expression concordance between PTs and paired metastases in 100 patients with UC managed in the real-world setting....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Denmark

Share to Mutation

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35616216
DOI: 10.1111/apm.13249
PMCID: PMC9545015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 expression and FGFR-mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study.PMID 35616216Read ↗

Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data.Semantic proximity Read ↗

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial CancerSemantic proximity Read ↗

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Semantic proximity Read ↗

Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.Semantic proximity Read ↗

PD-L1 expression in Advanced Urothelial Carcinomas in two reference institutions in Colombia.Semantic proximity Read ↗

FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation SequencingSemantic proximity Read ↗

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.Semantic proximity Read ↗

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.Semantic proximity Read ↗

Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.Semantic proximity Read ↗

Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.Semantic proximity Read ↗

FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma.Semantic proximity Read ↗

PD-L1 Tumor Cell Expression in Upper Tract Urothelial Carcinomas is Associated with Higher Pathological StageSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.